NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Early Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Standard-of-Care
Sponsor: West German Study Group
Collaborators: AstraZeneca